MEDGADGET
ECHOJOURNAL
POPULAR
PASSMIX
CATEGORIES
SUBSCRIBE
SUBMIT
ABOUT
+ FOLLOW
✏ SUBMIT PR
* LOG IN
Latest Research On Erdosteine Market Growth and Industrial Forecast 2016-2024
MARCH 10TH, 2017
TRANSPARENCY MARKET RESEARCH
Google+
RELEASES
RECENT POSTS Jet Powered Pill Shoots Vaccine Into Cheek to Avoid Injections
Convert webpages to pdf online w ith PDFmyURL
Erdosteine is an oral mucolytic agent used for treatment of
ZOLL's Hospital Wearable Defibrillator FDA Approved
chronic obstructive bronchitis. Erdosteine is also used for treatment of acute and chronic bronchitis. It is an orphan drug. Erdosteine stimulates mucus
Japanese Researchers Develop New Filter to Use microRNA as Disease Biomarker
production and increases mucociliary transport, which improves expectoration. It consists of two sulfhydryl groups
Tiny Paper Pumps to Power Microfluidic Devices
freed after metabolic transformation in the liver. These released sulfhydryl groups help to break the disulphide bonds. This makes bronchial secretions more fluid and enhances elimination. Erdosteine shows inhibitory activity against the effects of free radicals produced by cigarette smoke. Pharmacokinetically,
Method Spots Bacterial Infections in Root Canals to Improve Success, Prevent Additional Procedures
it acts by absorption, distribution, metabolism, and excretion. The elimination half-life of Erdosteine is about 1.46 hr. Adverse events of Erdosteine are quite low, and generally mild. It has been clinically proven that Erdosteine has good gastric tolerability after oral administration, and does not cause reflux phenomena like other thiols derivatives. Erdosteine has no direct effect on
INTERV IEWS & REV IEWS Koogeek S1 Smart Health Scale Review
gastric mucus. Brow se Mark et Research Report @ h ttp://w w w .tran sparen cy m ark etresearch .com /erdostein e-m ark et.h tm l Increasing prevalence of respiratory diseases, rising geriatric population, rapid population growth, and environmental pollution due to industrialization are expected to fuel the global erdosteine market. According to the WH O, chronic obstructive pulmonary disease (COPD) accounts for three Convert webpages to pdf online w ith PDFmyURL
Medgadget's Coverage of the Inaugural AdvaMed Digital MedTech Conference
million deaths globally each year and the number is expected to increase in the next few years. About 90% of chronic obstructive pulmonary disease (COPD) deaths occur in developing and underdeveloped countries. Rising research and development activities, increasing health care insurance coverage, and growing adoption for treatment options are the other factors driving the global erdosteine market. On the other hand, stringent regulations for product approval are likely to hamper the growth of the global erdosteine
Anders Wold, GE Healthcare’s CEO of Clinical Care Solutions on What To Think About When Running a Medtech Business
CleanSlate UV Sanitizer for Mobile Devices in Healthcare: An Interview
market. Erdosteine is used for rare diseases so maximum companies doing research and development which will increase the market competitiveness. Erdosteine is marketed in over 40 countries for the treatment of various respiratory diseases. The erdosteine market has been segmented based on dosage form, age group, application, distribution channel, and region. In terms of dosage form, the market has been classified into capsules, dry suspension, dispersible tablets, and sachets. The capsule dosage form is highly used due to ease of use, availability in unit dosage form, and also easy in term of prescription scenario which will leads to less side effect. Based on age group, the erdosteine market has been segmented into adult and pediatric. In terms of application, the market has been classified into chronic obstructive pulmonary disease (COPD), acute bronchitis (AB), and chronic bronchitis (CB). Based on distribution channel, the erdosteine market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of region, the market has been segmented into N orth America, Latin America, Europe, Asia Pacific, and Middle East & Africa. N orth America dominated the erdosteine market due to rising geriatric population, early adoption of treatment procedures, and increasing prevalence of respiratory diseases. The geriatric population represents about 14.5% of the population of the U.S. According to the U.S. Department of H ealth and H uman Service, the geriatric population will increase to 98 million by 2060, which is Convert webpages to pdf online w ith PDFmyURL
Improving Patient Engagement through Artificial Intelligence: Interview with Gilad Meiri, CEO & Co-Founder of Neura
twice that in 2014. Europe is the second largest market for erdosteine attributed to increasing research and development activities and rising number of commercial licensing partnerships for erdosteine manufacturing. Asia Pacific is expected to grow at a higher rate driven by growing per capita expenditure, increasing health care insurance coverage, rapidly growing population, and rising per capita health care expenditure. Major players operating in the erdosteine market include Edmond Pharma S.R.L., Alitair Pharmaceuticals, Manus Aktteva Biopharma LLP, Enaltec, Reine Life Science, Taj Pharmaceuticals Ltd., Recipharm AB, Glenmark Pharmaceuticals Ltd., Sigma-Aldrich Co. LLC, Genome Pharmaceuticals (Pvt.) Ltd., and Milan Pharma. Fill th e form to gain deeper in sigh ts on th is m ark et @ h ttp://w w w .tran sparen cy m ark etresearch .com /sam ple/sam ple.ph p? flag=B& rep_id=19166 The report offers a comprehensive evaluation of the market. It does so via indepth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications. U S Office Con tact 90 State Street, Suite 700 Albany, N Y 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Em ail: sales@ tran sparen cy m ark etresearch .com Convert webpages to pdf online w ith PDFmyURL
W ebsite: h ttp://w w w .tran sparen cy m ark etresearch .com /
Sign up and submit a press release
RELATED POSTS RELEASES
RELEASES
RELEASES
MARCH 10TH, 2017
MARCH 10TH, 2017
MARCH 10TH, 2017
Global Medical Aesthetic Devices Market: Low-cost Products and Services could Hamper Growth across Emerging Economies, observes TMR
Application of Prepacked Chromatography Columns in Pharmaceutical Biotechnology on the Rise, notes TMR
North America Wheelchair Accessible Vehicle Converters Market: Growing Usage of Mobility Assistive Devices to Augur Well for WAV Manufacturers, projects TMR
Convert webpages to pdf online w ith PDFmyURL
RELEASES
RELEASES
RELEASES
MARCH 10TH, 2017
MARCH 10TH, 2017
MARCH 10TH, 2017
Changing Disease Profile Responsible for Rising Demand for Technetium-99m in MEA, finds TMR
Single-use Bioprocessing Systems Market: Customizability as per Consumer Requirements Key Feature Driving Adoption, reports TMR
Global Orthopedic Braces & Supports, Casting, & Splints Market: Growing Incidence of Sports Injuries Expected to Drive Demand, predicts TMR
SUBSCRIBE
CONTACT US
SUBMIT
ABOUT
At Medgadget we report on the latest medical technology news, interview leaders in the field, and file dispatches from medical events from around the world.
© Medgadget, LLC. 2004-2016. All rights reserved. | The Medical Revolution Will Be Blogged.
Convert webpages to pdf online w ith PDFmyURL
BACK TO TOP
About
Contact
Terms of Service
Privacy
Submit press release Advertise